ResearcherMayo ClinicNo recent work listed

Mark A. McNiven

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-9830-1885; OpenAlex author ID A5078792502. Sources: OpenAlex.

Their work

Papers: 2 (first author 0, last author 2)
Trials: 0
Grants: 0
Labs led: 1
Collaborators: 3

Papers, trials and grants by year

2015: 1 paper · 2016: none · 2017: none · 2018: 1 paper

Papers 2

Interleukin-6 promotes pancreatic cancer cell migration by rapidly activating the small GTPase CDC42. Last author DOI 10.1074/jbc.ra118.003276 ↗
Targeting Pancreatic Cancer Metastasis by Inhibition of Vav1, a Driver of Tumor Cell Invasion. Last author DOI 10.1158/0008-5472.can-14-3103 ↗

Closest collaborators

The 3 strongest of 3 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Gina Lynn Razidlo · 2 shared papers, 2015–2018 · strength 0.19
- Paper Interleukin-6 promotes pancreatic cancer cell migration by rapidly activating the small GTPase CDC42. DOI 10.1074/jbc.ra118.003276 ↗
- Paper Targeting Pancreatic Cancer Metastasis by Inhibition of Vav1, a Driver of Tumor Cell Invasion. DOI 10.1158/0008-5472.can-14-3103 ↗
Baoan Ji · 1 shared paper, 2015 · strength 0.05
- Paper Targeting Pancreatic Cancer Metastasis by Inhibition of Vav1, a Driver of Tumor Cell Invasion. DOI 10.1158/0008-5472.can-14-3103 ↗
Martín E. Fernández-Zapico · 1 shared paper, 2015 · strength 0.05
- Paper Targeting Pancreatic Cancer Metastasis by Inhibition of Vav1, a Driver of Tumor Cell Invasion. DOI 10.1158/0008-5472.can-14-3103 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.